Physician profile
Martin S Pine
NPI 1467587485
$1,204.04
in general payments reported to CMS, 2019-2025
11 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.15 · 2021: $111 · 2022: $266 · 2023: $315 · 2024: $198 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.10 |
| Education | $212.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $367.83 | 2019-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $261.97 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $194.94 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $143.27 | 2022-2025 | Dupixent |
| Optinose US, INC. | $84.44 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $45.26 | 2021-2024 | |
| Aerin Medical INC. | $38.85 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $30.93 | 2025 | Neffy |
| Organon LLC | $12.79 | 2025 | Vtama |
| Kaleo, INC. | $11.95 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Pine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.